News & Updates

3 अक्तूबर 2013

Long term agreement with Jinyu Baoling to produce brucellosis vaccines in China >

Ceva concludes long term agreement with Jinyu Baoling to produce brucellosis vaccines in China

23 सितंबर 2013

Ceva launches Fertipig® in Asia >

New product gives swine producers “power with control”

20 सितंबर 2013

Ceva support to the 11th IFCN Dairy Conference >

This year for the 11th time, leading dairy related companies came together at the IFCN Supporter Conference, held September 16th to 18th 2012 in Oxford, UK. IFCN stands for International Farm Comparison Network. This researcher’s organization provides the latest global information on milk production and the overall sector developments.

26 अगस्त 2013

Ceva stresses the need for more INNOVATION in the hatchery to drive growing global demand for poultry meat >

Company launches Cevac IBird ® a live, attenuated IB vaccine, to add to its portfolio of 16 new technology vaccines

25 अगस्त 2013

Ceva launches new Vectormune ® website >

Website provides educational resources for poultry professionals, as well as comprehensive information about their vector vaccines range.

20 अगस्त 2013

Ceva stresses the need for more INNOVATION in the hatchery to drive growing global demand for poultry meat >

Company launches Cevac IBird ® a live, attenuated IB vaccine, to add to its portfolio of 16 new technology vaccines

20 अगस्त 2013

Ceva souligne la nécessité d’une plus grande INNOVATION dans le couvoir pour répondre à la demande mondiale croissante pour la viande de volaille >

La société lance Cevac IBird ® un vaccin vivant atténué contre le virus IB, qui vient s’ajouter à son portefeuille de 16 vaccins élaborés grâce aux nouvelles technologies

26 जुलाई 2013

Ceva will be at the 18th World’s Poultry Congress >

Congress Center, Nantes Events Center «La Cité»

22 जुलाई 2013

Ceva’s growth continues despite difficult market conditions >

Libourne, France, 22 July, 2013: Consolidated sales of the Ceva Group reached €310m in the first 6 months of 2013, up by 2%, 4.2% on the previous year at a constant perimeter and exchange rates. Ceva recorded solid growth of 9% on a constant basis (constant perimeter and exchange rates), if one excludes 2 factors:  Vectra® sales in the United States, which were less than anticipated, due to a...

13 जून 2013

Ceva signs a Joint-venture agreement in China to help control zoonoses >

Joint-venture with Jinyu Baoling will produce brucellosis vaccines in Inner Mongolia

Back to top